Snake bite company snares new CEO

Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive.

Mr Gowler replaces Nancy Koch, who is retiring after spending nearly six years in the top job at the California-based firm. She will remain with the company as a non-voting member of the board of directors and a member of the global access committee. 

Prior to Ophirex, Mr Gowler was chief operating officer and chief commercial officer, as well as interim chief executive, of Invivyd (Nasdaq: IVVD), a biopharma company developing therapies to address evolving viral threats.